Roche at ASCO GU 2019
The 2019 Genitourinary (GU) Cancers Symposium is designed to meet the needs of professionals working with GU malignancies. Through educational sessions, abstract presentations and keynote lectures, among other formats, attendees can learn about the latest research findings and advancements within the field.
Feb 15, 2019 | OncologyFeb 15, 2019 | Oncology
This poster presents the first analysis of atezolizumab monotherapy use in patients with mUC treated in routine clinical practice in the US. 1L and 2L+ treatment data from the Flatiron Health EHR-derived database were compared with data from the IMvigor210 and IMvigor211 clinical trials. Time on treatment, distribution of treatment cycles and patient characteristics by treatment are reported.
Feb 15, 2019 | Oncology
ASCO-GU_Poster_2019 Long-term outcomes in elderly patients (pts) from IMvigor210: atezolizumab (atezo) in metastatic urothelial cancer (mUC)Feb 15, 2019 | Oncology
This poster presents results from a post-hoc analysis investigating the efficacy and safety of atezolizumab monotherapy in IMvigor210 patients with mUC ≥ 65 and ≥ 75 years. In this post hoc analysis, ORR, DOR, OS and safety were evaluated in subgroups based on age and PD-L1 status.